# A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours)

> **NCT07744152** · PHASE1 · RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 137 (estimated)

## Conditions studied

- Solid Tumours

## Interventions

- **DRUG:** BI 3822971

## Key facts

- **NCT ID:** NCT07744152
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-21
- **Primary completion:** 2030-01-15
- **Final completion:** 2030-01-15
- **Target enrollment:** 137 (ESTIMATED)
- **Last updated:** 2026-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07744152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07744152, "A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07744152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*